SCHEMBL6024236

SCHEMBL6024236

CCCCC[C@H](CN(O)C=O)C(=O)NNC(=O)c1cc2cc(OC)ccc2o1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 8/20 0.57
MMP12 P39900 2/20 0.57
TAS1R3 Q7RTX0 9/20 0.53
TAS1R1 Q7RTX1 9/20 0.53
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068544 0.90 BMP1 (0.71) BMP1MMP12TAS1R3TAS1R1HDAC3
SCHEMBL6024763 0.88 BMP1 (0.53) BMP1MMP12TAS1R3TAS1R1HDAC3
SCHEMBL6024483 0.88 BMP1 (0.53) BMP1MMP12TAS1R3TAS1R1HDAC3
SCHEMBL6024195 0.86 BMP1 (0.59) BMP1MMP12TAS1R3TAS1R1HDAC3
SCHEMBL6024186 0.85 BMP1 (0.50) BMP1MMP12TAS1R3TAS1R1HDAC3
SCHEMBL11889610 0.81 BMP1 (0.61) BMP1MMP12TAS1R3TAS1R1
SCHEMBL6024091 0.81 BMP1 (0.54) BMP1MMP12TAS1R3TAS1R1HDAC3
SCHEMBL6023908 0.80 BMP1 (0.63) BMP1MMP12TAS1R3TAS1R1
SCHEMBL6024298 0.79 BMP1 (0.52) BMP1MMP12
SCHEMBL6024587 0.79 BMP1 (0.66) BMP1MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363873-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-04-20 EP claimed
US-7019003-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-03-28 US claimed
US-20040087585-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-05-06 US claimed
EP-1363873-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-04-20 EP disclosed
US-7019003-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-03-28 US disclosed
EP-1363873-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP disclosed
US-20040087585-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-05-06 US disclosed
EP-1363873-A2 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2003-11-26 EP disclosed
WO-2002070541-A2 PEPTIDE DEFORMYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087585-A1 Peptide deformylase inhibitors PDF, DPEP1, PEPD BMP1 1586/4885MMP12 1038/4885TAS1R3 3429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.